M9466

DRUG3 trials

Sponsors

EMD Serono Research & Development Institute, Inc.

Conditions

Advanced Solid TumorAdvanced Solid Tumors

Phase 1

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

Active, not recruitingNCT06421935

EMD Serono Research & Development Institute, Inc.Advanced Solid Tumor

Start: 2024-08-07End: 2027-02-22Target: 141Updated: 2026-03-24

M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)

TerminatedNCT06509906

EMD Serono Research & Development Institute, Inc.Advanced Solid Tumor

Start: 2024-10-08End: 2025-12-02Updated: 2025-12-18

Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)

WithdrawnNCT06719973

EMD Serono Research & Development Institute, Inc.Advanced Solid Tumors

Start: 2025-05-14End: 2025-05-14Updated: 2025-06-17

Related Papers

Abstract 1171: M9466 (HRS-1167): A highly potent and selective PARP1 inhibitor with DNA trapping activity, monotherapy antitumor activity and synergistic potential with DDR inhibitors and chemotherapies

Cancer Research2025-04-21